• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺导管原位癌(DCIS):生物学视角与当前管理争议

Ductal carcinoma in situ (DCIS) of the breast: perspectives on biology and controversies in current management.

机构信息

Division of Breast and Soft Tissue Surgery, Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

出版信息

J Surg Oncol. 2012 Feb;105(2):212-20. doi: 10.1002/jso.22020. Epub 2011 Jul 12.

DOI:10.1002/jso.22020
PMID:21751217
Abstract

The incidence of ductal carcinoma in situ (DCIS) has increased because of increasing use of sensitive imaging modalities. MRI is commonly used for the detection of breast cancer but has not yet been validated in randomized trials. There have not been randomized trials addressing optimal margins of excision or axillary sampling. Whole breast radiation after lumpectomy decreases the risk of recurrence but may be omitted in selected patients. Adjuvant Tamoxifen reduces the risk of recurrence but has no impact on overall survival rates.

摘要

由于敏感成像方式的广泛应用,导管原位癌(DCIS)的发病率有所增加。磁共振成像(MRI)常用于乳腺癌的检测,但尚未在随机试验中得到验证。目前尚无针对最佳切除边缘或腋窝取样的随机试验。保乳手术后行全乳腺放疗可降低复发风险,但在某些特定患者中可以省略。辅助他莫昔芬可降低复发风险,但对总生存率无影响。

相似文献

1
Ductal carcinoma in situ (DCIS) of the breast: perspectives on biology and controversies in current management.乳腺导管原位癌(DCIS):生物学视角与当前管理争议
J Surg Oncol. 2012 Feb;105(2):212-20. doi: 10.1002/jso.22020. Epub 2011 Jul 12.
2
Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives.乳腺导管原位癌:不断演变的观点
Cancer Treat Rev. 2000 Apr;26(2):103-25. doi: 10.1053/ctrv.1999.0149.
3
Current management of DCIS: a review.导管原位癌的当前管理:综述
Breast Cancer Res Treat. 2008 Sep;111(1):1-10. doi: 10.1007/s10549-007-9760-z. Epub 2007 Sep 28.
4
Treatment of ductal carcinoma in situ of the breast: review of recent advances and future prospects.乳腺导管原位癌的治疗:近期进展与未来前景综述
Int J Fertil Womens Med. 2003 Sep-Oct;48(5):217-25.
5
Optimal management of ductal carcinoma in situ of the breast.乳腺导管原位癌的优化管理
Surg Oncol. 2003 Dec;12(4):221-40. doi: 10.1016/S0960-7404(03)00031-8.
6
Contemporary treatment of ductal carcinoma in situ of the breast.当代乳腺导管原位癌的治疗
Med Sci Monit. 2005 Mar;11(3):RA86-93.
7
Current perspectives of treatment of ductal carcinoma in situ.当前对导管原位癌治疗的看法。
Cancer Treat Rev. 2010 Nov;36(7):507-17. doi: 10.1016/j.ctrv.2010.03.007. Epub 2010 May 11.
8
Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials.他莫昔芬联合放疗和手术治疗乳腺导管原位癌的疗效:两项随机试验的荟萃分析
Radiother Oncol. 2011 Aug;100(2):195-9. doi: 10.1016/j.radonc.2011.02.005. Epub 2011 Mar 14.
9
Treatment of ductal carcinoma in situ after excision: would a prophylactic paradigm be more appropriate?切除后导管原位癌的治疗:预防性范式是否更合适?
J Natl Cancer Inst. 2013 Oct 16;105(20):1527-33. doi: 10.1093/jnci/djt256. Epub 2013 Sep 25.
10
The dilemma of DCIS.导管原位癌的困境
Breast. 2007 Dec;16 Suppl 2:S59-62. doi: 10.1016/j.breast.2007.07.015. Epub 2007 Aug 21.

引用本文的文献

1
Large and diffuse ductal carcinoma in situ: potentially lethal subtypes of "preinvasive" disease.大而弥漫性导管原位癌:“浸润前”疾病的潜在致命亚型。
Int J Clin Oncol. 2022 Jan;27(1):121-130. doi: 10.1007/s10147-021-02036-1. Epub 2021 Oct 7.
2
Preoperative breast magnetic resonance imaging in patients with ductal carcinoma in situ: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC).术前乳腺磁共振成像在导管原位癌患者中的应用: 欧洲委员会乳腺癌倡议(ECIBC)的系统评价。
Eur Radiol. 2021 Aug;31(8):5880-5893. doi: 10.1007/s00330-021-07873-2. Epub 2021 May 30.
3
Long-Term Outcomes of Sentinel Lymph Node Biopsy for Ductal Carcinoma in Situ.
导管原位癌前哨淋巴结活检的长期结果
JNCI Cancer Spectr. 2019 Aug 7;3(4):pkz052. doi: 10.1093/jncics/pkz052. eCollection 2019 Dec.
4
FAP-a and GOLPH3 Are Hallmarks of DCIS Progression to Invasive Breast Cancer.FAP-a和GOLPH3是导管原位癌进展为浸润性乳腺癌的标志。
Front Oncol. 2019 Dec 17;9:1424. doi: 10.3389/fonc.2019.01424. eCollection 2019.
5
Advances in Breast MRI in the Setting of Ductal Carcinoma In Situ.导管原位癌背景下乳腺磁共振成像的进展
Semin Roentgenol. 2018 Oct;53(4):261-269. doi: 10.1053/j.ro.2018.08.006. Epub 2018 Aug 30.
6
Treatment patterns for ductal carcinoma in situ from 2000-2010 across six integrated health plans.2000年至2010年期间,六个综合健康计划中导管原位癌的治疗模式。
Springerplus. 2015 Jan 17;4:24. doi: 10.1186/s40064-014-0776-7. eCollection 2015.
7
Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.他莫昔芬通过蛋白磷酸酶2A的癌性抑制剂依赖性磷酸化Akt失活在雌激素受体阴性的人乳腺癌细胞中诱导细胞凋亡。
Breast Cancer Res. 2014 Sep 17;16(5):431. doi: 10.1186/s13058-014-0431-9.
8
Human epidermal growth factor receptor 2-positive microinvasive breast carcinoma with a highly aggressive course: a case report.具有高度侵袭性病程的人表皮生长因子受体2阳性微浸润性乳腺癌:一例报告
BMC Res Notes. 2014 May 31;7:325. doi: 10.1186/1756-0500-7-325.